Pharmaceutical Technology

DECEMBER 9, 2022

Our QC testing capabilities range from solids, semi-solids and liquids for oral, inhaled and injectable use to packaging materials, including rubber closures, glass and plastic containers. All our equipment is in line with the latest European Medicines Agency (EMA) and FDA methods.

Development 130

Development Production Manufacturing Vaccine 130

The Pharma Data

FEBRUARY 8, 2021

IBRANCE may impair fertility in males and has the potential to cause genotoxicity. At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. DISCLOSURE NOTICE : The information contained in this release is as of February 5, 2021.

HR 52

HR Clinical Trials Clinical Trials Containment 52

The Pharma Data

APRIL 14, 2021

Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor –. – New Indication Marks Second FDA Approval for Trodelvy in 2021 –. Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines.

Genotype 52

Genotype Containment FDA Approval Genotoxicity 52

The Pharma Data

MAY 13, 2021

Fructose Containing Sugars at Normal Levels of Consumption Do Not Effect Adversely Components of the Metabolic Syndrome and Risk Factors for Cardiovascular Disease. Exposure to sorbitol during lactation causes metabolic alterations and genotoxic effects in rat offspring. The Yale Journal of Biology and Medicine. PMID: 25003263.

Insulin 52

Insulin Production Hormones Medicine 52

The Pharma Data

MARCH 25, 2021

Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines. Medicines targeting these receptors therefore are not typically effective in treating TNBC. SG contains a genotoxic component and can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman.

Genotoxicity 52

Genotoxicity Genotype Containment Protein 52

The Pharma Data

APRIL 7, 2021

“Women with triple-negative breast cancer have historically had very few effective treatment options and faced a poor prognosis,” said Aditya Bardia, MD, MPH, Director of Breast Cancer Research Program, Mass General Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and global principal investigator of the ASCENT study.

HR 52

HR Genotype FDA Approval Genotoxicity 52